secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADAPTIN BIO, INC. (APTN)
CIK:        0001938571
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001213900-25-030320
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial
--------------------------------------------------------------------------------

- Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.
- Private placement of 1,400,342 shares with Series A (1-yr, $4.40) and Series B (5-yr, $6.60) warrants.
- $1.5M promissory notes converted at $3.30/share; total gross proceeds ~$7.7M.
- Proceeds to fund Phase 1 trial of APTN-101 for glioblastoma after FDA IND clearance.
- Post-closing: Lucius Partners and former Adaptin holders each hold ~3.25M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938571/000121390025030320/0001213900-25-030320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938571/000121390025030320/ea0237436-8k_adaptin.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-030320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer